These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Intravitreal steroids for macular edema in diabetes. Rittiphairoj T; Mir TA; Li T; Virgili G Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005656. PubMed ID: 33206392 [TBL] [Abstract][Full Text] [Related]
4. Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trials. Holden SE; Kapik B; Beiderbeck AB; Currie CJ Curr Med Res Opin; 2019 Jul; 35(7):1165-1176. PubMed ID: 30569759 [No Abstract] [Full Text] [Related]
7. Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema. Pessoa B; Coelho J; Correia N; Ferreira N; Beirão M; Meireles A Ophthalmic Res; 2018; 59(2):68-75. PubMed ID: 29248913 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 µg intravitreal implant in people with diabetic macular edema. Holden SE; Currie CJ; Owens DR Curr Med Res Opin; 2017 Oct; 33(sup2):5-17. PubMed ID: 28881149 [TBL] [Abstract][Full Text] [Related]
10. Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment. Rehak M; Busch C; Unterlauft JD; Jochmann C; Wiedemann P Acta Diabetol; 2020 Apr; 57(4):469-478. PubMed ID: 31749051 [TBL] [Abstract][Full Text] [Related]
11. Real-world experience with 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom. Bailey C; Chakravarthy U; Lotery A; Menon G; Talks J; Eye (Lond); 2017 Dec; 31(12):1707-1715. PubMed ID: 28737758 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of the clinical effectiveness of fluocinolone acetonide 190 µg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes. Currie CJ; Holden SE; Berni E; Owens DR Curr Med Res Opin; 2017 Oct; 33(sup2):19-31. PubMed ID: 28881143 [TBL] [Abstract][Full Text] [Related]
13. Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant. Ciulla TA; Harris A; McIntyre N; Jonescu-Cuypers C Expert Opin Pharmacother; 2014 May; 15(7):953-9. PubMed ID: 24661081 [TBL] [Abstract][Full Text] [Related]
14. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Pearson PA; Comstock TL; Ip M; Callanan D; Morse LS; Ashton P; Levy B; Mann ES; Eliott D Ophthalmology; 2011 Aug; 118(8):1580-7. PubMed ID: 21813090 [TBL] [Abstract][Full Text] [Related]
15. Report of 12-months efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: a real-world result in the United Kingdom. Alfaqawi F; Lip PL; Elsherbiny S; Chavan R; Mitra A; Mushtaq B Eye (Lond); 2017 Apr; 31(4):650-656. PubMed ID: 28106887 [TBL] [Abstract][Full Text] [Related]
16. The Outcomes of Switching from Short- to Long-Term Intravitreal Corticosteroid Implant Therapy in Patients with Diabetic Macular Edema. Vaz-Pereira S; Castro-de-Sousa JP; Martins D; Prates Canelas J; Reis P; Sampaio A; Urbano H; Kaku P; Nascimento J; Marques-Neves C Ophthalmic Res; 2020; 63(2):114-121. PubMed ID: 31801148 [TBL] [Abstract][Full Text] [Related]